Medical Director
PhaseV is redefining how clinical trials are designed and run. Using advanced causal machine learning and generative AI, we help biopharma and biotech companies make faster, more accurate, and more efficient development decisions — detecting hidden signals in clinical data and turning them into actionable insights across the trial lifecycle.
Headquartered in Cambridge, MA with our R&D and medical teams based in Tel Aviv, PhaseV is backed by leading investors including Insight Partners and Accel, and has raised $65M to date. We work with top pharmaceutical companies, biotechs, and CROs — and our platform has driven reported outcomes of up to 40% reductions in enrollment time, 50% lower trial costs, and 30%+ higher probability of trial success.
Our platform is built around four core modules:
- Response Optimizer — uncovers patient response heterogeneity to identify optimal treatment populations
- Trial Optimizer — designs adaptive, Bayesian trial designs tailored to sponsor objectives
- Portfolio Optimizer — uses causal graphs to inform portfolio-level development decisions
- Clin Ops Optimizer — applies causal ML to site selection and real-time trial performance
